Skip to main content
Livermore
Livermore
ZHEN

Vir Biotechnology, Inc.

VIR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001706431

No open-market purchases or sales by Vir Biotechnology, Inc. insiders were filed in the last 90 days; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Vir Biotechnology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Vir Biotechnology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Vir Biotechnology, Inc.
NameTitleLast reported holdingLast filingFilings, past year
More Robert JDirector517,917IndirectAug 12, 20262
Coughlin TimothyDirector16,000Jun 10, 20261
Napolitano JanetDirector21,216Jun 2, 20262
Sabatini BrentSVP, Chief Accounting Officer61,902Jun 2, 20265
Bischofberger Norbert WDirector21,333May 28, 20261
Hatfield Jeffrey S.Director39,806May 28, 20261
Sigal Charles ElliottDirector39,806May 28, 20261
Farid RamyDirector32,000May 28, 20261
Sato Vicki LDirector1,078,391May 4, 20269
De Backer MariannePresident and CEO286,650IndirectApr 30, 20264
O'Byrne JasonEVP & Chief Financial Officer2,500IndirectMar 23, 20264
Eisner MarkEVP and Chief Medical Officer154,024Feb 26, 20262
de Verneuil VaninaEVP, General Counsel, Corp Sec112,982Feb 26, 20264
SB Investment Advisers (UK) Ltd10% Owner13,728,924IndirectDec 3, 202511
Softbank Vision Fund (Aiv M1) L.P.10% Owner13,728,924IndirectDec 3, 202511
SVF Endurance (Cayman) Ltd10% Owner13,728,924IndirectDec 3, 202511
Ramasastry SairaDirector22,619Jun 2, 20250
Scangos George ADirector698,239Feb 25, 20250
Hanly Ann M.EVP & Chief Technology Officer117,901Feb 25, 20250
Nelsen RobertDirector584,148Jun 3, 20240
Lee SungEVP & Chief Financial Officer100,492Mar 28, 20240
Pang PhillipEVP & Chief Medical Officer250,111Feb 26, 20240
Rice Steven J.Chief Administrative Officer106,840Jun 2, 20230
Sharp Phillip ADirector121,174May 24, 20230
Perez Robert JDirector15,806May 24, 20230
Friedl-Naderer JohannaEVP & Chief Operating Officer148,518Mar 7, 20230
Horn HowardCFO230,712Feb 24, 20230
Crandell Keith10% Owner61,160IndirectSep 7, 20220
Bybee Clinton10% Owner61,160IndirectSep 7, 20220
ARCH Venture Fund IX, L.P.10% Owner61,160IndirectSep 7, 20220
ARCH Venture Fund IX Overage, L.P.10% Owner61,160IndirectSep 7, 20220
ARCH Venture Partners IX Overage, L.P.10% Owner61,160IndirectSep 7, 20220
ARCH Venture Partners IX, L.P.10% Owner61,160IndirectSep 7, 20220
ARCH Venture Partners IX, LLC10% Owner61,160IndirectSep 7, 20220
Virgin HerbertEVP, Research & CSO262,500Aug 10, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 19, 2021 (view filing)Jul 154 daysMore Robert JDirectorSSale−11.7K$35.56−$415.0K−20.2%46.0K after
Jul 14, 2021 (view filing)Jul 131 dayVirgin HerbertEVP, Research & CSOSSale−1.38K$36.72−$50.5K−1.4%99.7K after
Jul 8, 2021 (view filing)Jul 71 dayPang PhillipChief Medical OfficerSSale−5.00K$40.38−$201.9K−4.4%109.3K after2 lots
Jul 6, 2021 (view filing)Jul 15 daysMore Robert JDirectorSSale−11.7K$44.93−$524.3K−16.8%57.7K after3 lots